《肿瘤与内分泌》.2005年.第2期
......
- Development of strategies for the use of anti-growth factor treatments
- Inhibitors of growth factor signalling
- Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy
- Clinical trials of intracellular signal transductions inhibitors for breast cancer — a strategy to overcome endocrine resistance
- Overview of tyrosine kinase inhibitors in clinical breast cancer
- Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy
- Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience
- Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience
- Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast canc
- Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X
- Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E
- Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation
- Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity
- The NFB pathway and endocrine-resistant breast cancer
- Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor t
- The epidermal growth factor receptor family
- Overview of the impact of conventional systemic therapies on breast cancer
- Polymer–drug conjugates: towards a novel approach for the treatment of endrocine-related cancer
- ER is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components
- Malign cystic glucagonoma presented with diabetic ketoacidosis: case report with an update
- Chromosomal instability predicts metastatic disease in patients with insulinomas
- Enhanced protein kinase B/Akt signalling in pituitary tumours
- Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inosi
- The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1
- Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human br
- Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement
- Alterations in the regulatory volume decrease(RVD) and swelling-activated Cl–current associated with neuroendocrine differentiation of pros
- Identification of growth factor independent-1(GFI1) as a repressor of 25-hydroxyvitamin D 1-alpha hydroxylase(CYP27B1) gene expression in
- BRAF mutation in thyroid cancer
- Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
- Characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical mark
- Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture
- Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and re
- Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis
- Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma
- Tissue inhibitor of metalloproteinases-1 in breast cancer
- Breast-tissue sampling for risk assessment and prevention
- Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis an